Donor Skin Patch Helps Patient Detect Lung Transplant Rejection

A pioneering medical trial in the United Kingdom is utilizing donor skin patches to provide an early warning system for organ rejection in lung transplant patients. This method involves grafting a small piece of skin from the organ donor onto the patient’s forearm at the time of the transplant, allowing clinicians to detect rejection visually before it causes permanent damage to the lungs.

The approach is part of the Sentinel trial, which is designed to revolutionize how lung transplant recipients are monitored. Scientists involved in the study believe that skin tends to reject earlier and more visibly than other internal organs. By using the skin patch as a window, medical teams can identify the appearance of a rash and intervene with treatment more rapidly than they could by relying on internal organ monitoring alone.

Case Study: Early Detection and Treatment

Darren White, a 53-year-old former bus driver from Stockton-on-Tees, County Durham, was one of the first patients in the UK to participate in the trial. In 2024, Mr. White was diagnosed with lung fibrosis, a condition characterized by lung scarring that leads to significant breathing difficulties. He underwent a lung transplant later in 2024.

Three months after his surgery, Mr. White developed a purple rash on the donor skin patch grafted to his forearm. This visible signal led to tests that confirmed his body was rejecting the new lung. Because the rejection was detected early, he was treated with steroids to manage the mild rejection.

More than a year after the transplant, Mr. White reports that he is doing well. He stated that the improved health allows him to be more of a dad to his toddler, Daniel, as he is now able to walk and take his son to the park.

The Sentinel Trial Framework

The Sentinel trial aims to recruit 152 patients and is scheduled to run until 2027. To date, 10 patients have received skin patches measuring 10cm by 3cm from their respective organ donors.

The primary goal of the study is to reduce the risk of permanent organ damage by slashing the time between the onset of rejection and the start of medical treatment. For transplant recipients, rejection is often cited as a primary concern; the skin patch provides a tangible way to monitor the body’s immune response in real-time.

Rejection is the biggest fear of any transplant recipient, so having something that might be able to catch it much sooner than otherwise was really appealing.

Darren White

Medical Context and Significance

Lung transplant recovery requires vigilant monitoring because the immune system may identify the new organ as foreign and attack it. Traditional monitoring methods may not always detect mild rejection in its earliest stages.

The Sentinel trial’s hypothesis rests on the visibility and reactivity of the skin. Because the skin patch comes from the same donor as the lung, it shares the same genetic markers. When the patient’s immune system begins to reject the donor’s tissue, the skin patch reacts in a way that is visible to the naked eye, serving as a proxy for the internal state of the transplanted lung.

By treating the rejection as soon as the rash appears, doctors can apply therapies, such as steroids, to stabilize the organ and prevent the scarring or failure that can occur if rejection goes unnoticed for longer periods.